SERES
13.1.2023 14:31:38 CET | Business Wire | Press release
For 36 years, SERES, a subsidiary of the eponymous Chinese group, has positioned itself as a premium smart e-vehicle brand. After five years of development and testing, the company is officially launching the cutting-edge, high-performing, high-tech SERES 5 in Europe. Available in three models (Standard version 2WD, Premium version 4WD, Flagship version 4WD) the SERES 5 is a sporty, premium e-SUV that blazes a new trail by combining the best of everything: design, smart driving, power, range and comfort. From January 14 to 22, visitors to the Brussels Motor Show will get an exclusive sneak peek at the premium sport E-SUV before it goes on sale in March.
Natural Aesthetics of Life
Many people sat up and took notice when the SERES 5 concept was unveiled in Silicon Valley. In particular, its design caught their eye as SERES5 is inspired by nature with flexibility, purity and vitality. Special attention was paid to the nature-inspired aesthetics (Σ front face, willow-inspired window, Belt line mimics dolphin’s leaping). The roofline continuously and uninterruptedly descends to the trunk, giving the vehicle an ultra-low wind resistance, making it more dynamic and more energy efficient 1. The SERES 5 is available in 8 exterior colours and 5 interior ones that can be combined as desired.
Zero to 100 km/h in 3.7 seconds and a range up to 530 km
Behind its premium design lies an amazing driving experience enhanced by a performance worthy of the market’s top models. The SERES 5 accelerates from 0 to 100 km/h in 3.7 seconds thanks to its front and rear motor peak power (430KW) and peak torque 960N.m.
To control acceleration and stabilize the vehicle, the chassis is mainly made of a strong, lightweight aluminium alloy. For a premium driving experience, a dual ball joint front double-wishbone front suspension enhances anti-roll performance and a multi-link trapezoidal arm type rear independent suspension improves stability.
The SERES 5 boasts an outstanding range. Its 80kWh lithium iron phosphate and 90 kWh semi solid state high performance batteries offer a significant power supply and high energy efficiency. Thus, on a single charge the 2WD model can travel 500 km WLTP and the 4WD can cover 530 km WLTP. They are compatible with 95% of the charging systems available in Europe. Moreover, SERES 5 includes a smart fast charging system: a quick recharge to shorten the waiting time on the way and, on camping ground, a V2L function can provide power to many travel appliances such as induction cookers and coffee makers, while the V2V function can also help charge other people’s EV’s in emergency.
The SUV is also equipped with an industry leading permanent magnet motor: a little technological gem.
A safe, unparalleled driving experience
The SERES 5 also stands out for its 18 assisted-driving features, +300 smart voice assistants (8 active service reminders, 14 telephone operations, 17 navigation operations, 35 multimedia operations, ...), 3 smart scenarios (rest mode, temporary stop mode, camping mode) and over 20 "Smart Car Ecology" devices (on-line map, On-line music, car game, DAB digital radio).
As a safety feature, voice commands let the driver control everything from air conditioning to music while keeping both hands on the wheel and eyes on the road. The SERES 5 also has LFP batteries and, for the first time, a semi-solid battery as standard equipment that has undergone around 100 tests, with a long service life (100,000 km without degradation) and high peak power (430 KW). What’s more, the SERES 5 benefits from a five-level safety management system and has travelled the equivalent of 5.000.000 km in extreme conditions (cold, heat, high altitudes, etc.) to ensure optimal use. To provide the best of breed, the brand has also gathered a global supply chain system of experts (Astemo, Longhorn, Bosch, Valeo, Pirelli, BASF, …) around its SERES 5.
Finally in order to provide worry-free travel to its customers, SERES offers two outstanding warrantees: a 8 years (160.000 km) warranty for the battery, electric motor and electric control system and a 4 years (100.000 km) warranty for the vehicle. Besides, SERES 5 drivers will benefit from a 24hours emergency rescue road service, as well as online and offline customer services to all SERES valued customer.
Custom-made comfort for stress-free driving
SERES takes pride in putting technology to work for drivers and passengers with intelligent interiors geared to their needs. For example, instead of displaying all the features on a single central screen, three of them are arrayed around the driver to make the important messages visible while ensuring that the view is clear at every angle (HUD, 15.6” large central control screen, 12.3” LCD dashboard).
For a comfortable ride, the front seat can be adjusted in 12 different ways and is equipped with various settings such as ventilation, heating, memory, massage ... The SERES 5 also has two 40W wireless fast chargers (front and rear) to meet a wide variety of needs. The optional 85-inch deluxe panoramic skyline (field ratio 97.7%) offers a wide range of view while giving a unique impression of space. Lastly, new soundproofing and heat insulation materials keep the inside very quiet whatever the speed.
At the press conference, Mr. John Zhang, the chairman and founder of SERES Group emphasized that “In making SERES into a high-end, intelligent new energy vehicle brand, starting 2016, the group had consistently invested over 10% of its total revenue each year in Intelligent EV technologies. We have built industry 4.0 standard Intelligent factories, have developed and launched high-performance battery and range of other intelligent EV related products. Today these technologies are not only leading the sector in China but are considered to be on an advanced level on a global scale.”
The SERES 5 will be available from the brand's European sales network in March
Dimensions: 4710 x 1930 x 1620 mm
Standard version 2WD: from €63,9002
Premium version 4WD: from €67,900
Flagship version 4WD: from €74,900
1278 Cd drag coefficient
2 indicative prices for the German market
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230113005191/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
